Navigation Links
GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
Date:5/29/2008

Data Showed Clinically Meaningful Benefits for Patients with Chemotherapy-Induced Nausea and Vomiting

PHILADELPHIA and LONDON, May 29 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) today announced the submission of a new drug application to the U.S. Food and Drug Administration and new data from two Phase III trials for Rezonic(TM)/Zunrisa(TM) (casopitant), a novel, investigational NK-1 receptor antagonist. The data demonstrated a significant and clinically meaningful reduction in the number of patients experiencing chemotherapy-induced nausea and vomiting (CINV). Adding a single oral dose regimen of casopitant to the standard dual therapy of Zofran(R) (ondansetron HCI) and dexamethasone, achieved this effect in patients taking highly emetogenic chemotherapy (HEC) and those on moderately emetogenic chemotherapy (MEC) treatment regimens.(1,2) CINV can be a serious, feared and distressing side effect of chemotherapy for patients and their families.(3) CINV can last for about five days and the risk of nausea and vomiting without prophylaxis is greater than 90 percent for patients receiving HEC and 30-90 percent for patients receiving MEC.(4,5)

Data from the two Phase III clinical trials demonstrated complete response rates of 86 percent for those patients given a single oral dose of casopitant together with the standard dual therapy in the HEC trial, and 73 percent for patients given either single oral or three-day oral doses of casopitant together with the standard dual therapy in the MEC trial.(1,2) This prophylactic treatment resulted in clinically meaningful and statistically significant improvements compared to controls.(1,2) To achieve complete response, patients had no vomiting or retching and took no rescue medications for five days following chemotherapy treatment.(1,2) These data for the single dose regimen - in addition to results for three-day oral and three-day IV/oral regimens - will be unveiled this week at the 44th Annual Meeting
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
6. GlaxoSmithKline Accelerates Review of Exelixis XL880
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Genmab Announces Updates on Phase III Cancer Studies
9. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
10. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
11. BioElectronics Announces Major Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Atlanta, GA (PRWEB) August 30, 2014 ... US Open Challenge and K.Warrior Search on November 8th, ... Over 20 years, these events have introduced many notorious ... such as Strike-Force, IWF and the UFC. , ... seen numerous fighters leave its doors armed with the ...
(Date:8/30/2014)... 30 August 2014: The first multidisciplinary recommendations on ... coronary syndromes (ACS) are published today in ... written jointly by the European Heart Rhythm Association ... the European Association of Percutaneous Cardiovascular Interventions (EAPCI), ... Gorenek (Turkey), chairperson of the task force, said: ...
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations on ... pulmonary embolism are published today in new ESC ... by Professor Stavros V. Konstantinides (Germany/Greece) and Professor ... on the diagnosis and management of acute pulmonary ... Journal (1) and on the ESC Website. , ...
(Date:8/29/2014)... Daily Gossip writes in its review that this is ... This method promises to teach readers how to eliminate the ... alternative sources for the production of energy. , Some ... solar power. , The Home Made Energy review indicates ... So, this is an online guide that will teach its ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Cancer ... loved ones and caretakers. Author Eddie M. Leung knows the ... cholangiocarcinoma or bile duct cancer, a very rare and ... That Changed My Life” (published by Xlibris), he shares a ... importantly, he imparts a survivor’s testimony that this disease can ...
Breaking Medicine News(10 mins):Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3
... may not be at,the top of your list of fun ... makes having any kind of fun a lot harder in ... your fiber intake, while enjoying the,benefits of regularity., Listen ... http://media.medialink.com/WebNR.aspx?story=35262 ., Registered journalists can access video, audio, text, ...
... Ind., June 19 Zimmer Holdings, Inc.,(NYSE: ... that it will partner with AmeriCares,one of ... donations, to support emergency response and ongoing ... at $1 million to,three of AmeriCares, primary ...
... a major international clinical trial coordinated by the Montreal ... England Journal of Medicine . The Atrial Fibrillation and ... project involving patients with heart failure and atrial fibrillation. ... the population and associated atrial fibrillation (a very common ...
... for diarrhea worldwide, study says , , THURSDAY, June 19 (HealthDay ... may help dysentery-causing amoeba evade the immune system. , ... fight dysentery, a form of diarrhea that affects about 500 ... threat in many regions. , "This is the first ...
... June 19 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ... and hospitals throughout the United States,today announced the final ... at 5:00 p.m. Eastern Time on Friday, June 13, ... depositary for the tender offer, an,aggregate of 2,240,883 shares ...
... June 19 Minneapolis-based Courage Center,is pleased to announce ... 2008,Eleven Who Care Agency of Distinction., Over the ... has,recognized the outstanding efforts of 264 (275 including 2008) ... amazing. Since the,awards began, 12 Courage Center volunteers (including ...
Cached Medicine News:Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 2Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 3Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3Health News:Scientists ID Enzyme That Allows Dysentery Amoeba to Hide 2Health News:NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share 2Health News:Courage Center Honored With KARE TV's 2008 Eleven Who Care Agency of Distinction 2
... with brass and aluminum body., ... suffix S to model number. Example: ... suffix C to model number. Example: ... Power Take-Off, add PT to model ...
... FM Series Oxygen Flowmeters with Power ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... proficiency testing solutions with outstanding customer service ... is one of the largest proficiency testing ... laboratories enrolled. Here are just some of ... Paperless Proficiency Testing, Free CME/CMLE Credits ...
... a new functional test which exhibits 100% ... C Resistance caused by the Factor V ... commercially available methods, Pefakit APC-R FVL shows ... Lupus Anticoagulants, Elevated FVIII levels, Heparins or ...
Medicine Products: